Every newborn deserves the best possible start in life. Newborn screening — a set of tests performed in the first days after birth — is one of the most powerful tools in preventive medicine. It detects genetic and metabolic disorders before symptoms appear, when early intervention can prevent serious health consequences, developmental delays, or even death.
In India, the Government has taken significant steps to expand newborn screening through the Rashtriya Bal Swasthya Karyakram (RBSK) under the National Health Mission — a comprehensive child health programme that includes newborn screening as a core component. States including Maharashtra, Karnataka, Kerala, and Gujarat have mandated newborn screening, reflecting a growing national commitment to early detection and intervention.
What Is Newborn Screening?
Newborn screening is a comprehensive set of tests performed shortly after a baby's birth — typically within 24–48 hours. These tests detect potential genetic, metabolic, hormonal, and functional disorders that may not be apparent at birth but could lead to serious health problems if left untreated.
The screening process is simple and minimally invasive:
- Heel prick blood test — A few drops of blood are collected from the baby's heel and applied to a filter paper card (Guthrie card) for laboratory analysis
- Hearing test (OAE/ABR) — A painless assessment of the newborn's auditory responses to detect hearing impairment
- Pulse oximetry — A non-invasive measurement of blood oxygen levels to screen for critical congenital heart disease
What Conditions Are Screened in India?
The conditions included in newborn screening programmes vary by state and hospital, but commonly include:
- Phenylketonuria (PKU) — Inability to metabolize phenylalanine; causes intellectual disability if untreated; managed with a low-phenylalanine diet
- Congenital hypothyroidism — Thyroid hormone deficiency at birth; causes growth and developmental delays if untreated; managed with thyroid hormone replacement
- Congenital adrenal hyperplasia (CAH) — Adrenal gland enzyme deficiency; can cause life-threatening salt-wasting crisis in newborns
- G6PD deficiency — Glucose-6-phosphate dehydrogenase deficiency; causes haemolytic anaemia triggered by certain foods and medications; highly prevalent in India
- Galactosaemia — Inability to metabolize galactose (a sugar in milk); causes liver damage, intellectual disability, and sepsis if untreated
- Biotinidase deficiency — Inability to recycle biotin; causes neurological damage if untreated; managed with biotin supplementation
- Cystic fibrosis — Genetic disorder affecting the lungs and digestive system
- Sickle cell disease and other haemoglobin disorders — Inherited red blood cell disorders; particularly prevalent in tribal and certain regional populations in India
- Amino acid metabolism disorders — Including maple syrup urine disease (MSUD) and homocystinuria
- Fatty acid oxidation disorders — Including MCAD deficiency; can cause sudden death in infancy if undetected
- Organic acid metabolism disorders — Including methylmalonic acidaemia and propionic acidaemia
Early identification of these conditions allows healthcare professionals to initiate treatment — dietary changes, enzyme replacement, hormone supplementation, or other interventions — before irreversible damage occurs.
The Power of Early Intervention: A Case Study
Phenylketonuria (PKU) illustrates the transformative impact of newborn screening. PKU is a genetic disorder in which the body cannot metabolize phenylalanine, an amino acid found in most protein-containing foods. Without treatment, phenylalanine accumulates in the brain, causing severe intellectual disability. With early detection through newborn screening and a low-phenylalanine diet started in the first weeks of life, children with PKU can develop normally and lead full, healthy lives. The difference between detection and non-detection is the difference between a normal life and profound disability.
Hearing Screening: A Critical Component
Hearing impairment is one of the most common congenital conditions — affecting approximately 1–3 per 1,000 newborns. Early detection through newborn hearing screening (using Otoacoustic Emissions [OAE] or Auditory Brainstem Response [ABR] testing) enables early intervention with hearing aids or cochlear implants, supporting normal language and cognitive development. Without early detection, hearing impairment can significantly delay speech and language acquisition.
The Future of Newborn Screening in India
Advances in genomic technology are expanding the scope of newborn screening. Two conditions of particular importance for the future of Indian newborn screening are:
- Duchenne Muscular Dystrophy (DMD) — A genetic disorder causing progressive muscle degeneration. Early detection enables earlier initiation of corticosteroid therapy and emerging gene therapies, potentially altering the course of the disease.
- Spinal Muscular Atrophy (SMA) — A motor neuron disorder causing progressive muscle wasting. Gene therapy (onasemnogene abeparvovec) is most effective when given before symptom onset — making newborn screening critical for access to this life-changing treatment.
Whole genome sequencing (WGS) as a newborn screening tool is also being explored in several countries — with the potential to screen for hundreds of genetic conditions simultaneously from a single blood sample.
Empowering Parents: What to Expect
For parents, newborn screening can feel overwhelming — particularly if a result comes back positive. It's important to understand that a positive screening result is not a diagnosis; it indicates that further confirmatory testing is needed. Most positive screening results turn out to be false positives. If a condition is confirmed, your healthcare team and genetic counsellors will guide you through the next steps, treatment options, and support resources.
FAQs
Is newborn screening mandatory in India?
Newborn screening is mandated in several Indian states (Maharashtra, Karnataka, Kerala, Gujarat) and is available through the RBSK programme nationally. Private hospitals increasingly offer expanded newborn screening panels. It is not yet universally mandated across all states.
What happens if my baby's newborn screening result is positive?
A positive result means your baby needs further confirmatory testing — it does not mean your baby definitely has the condition. Your paediatrician will arrange confirmatory tests and, if a condition is confirmed, refer you to a specialist and/or genetic counsellor for guidance on treatment and management.
🧬 MapmyGenome's Newborn and Paediatric Diagnostic Services
MapmyGenome's CAP & NABL-accredited diagnostic laboratory offers comprehensive newborn screening and paediatric genetic testing — including expanded metabolic screening, chromosomal analysis, and genetic counselling for families navigating a positive result.
For diagnostic testing enquiries: info@mapmygenome.in | 1800 102 4595
